Henry Schein has announced the appointment of Frederick M Lowery as its new chief executive officer, effective 2 Mar 2026. Lowery will also join the company’s board of directors. He succeeds Stanley M Bergman, who will step down after 35 years in the role and continue as chairman of the board to support the leadership transition.
Lowery brings more than 20 years of experience in healthcare distribution and operations. Most recently, he served as executive vice-president and president of laboratory products and bioproduction at Thermo Fisher Scientific, where he oversaw the performance of the Fisher Scientific distribution channel. His background includes leadership across distribution and owned-product businesses, encompassing manufacturing, research and development, marketing and sales, which aligns with Henry Schein’s business model.
Commenting on his appointment, Lowery said he was pleased to be joining Henry Schein at a significant point in its development and looked forward to working with the leadership team to build on the company’s existing foundations.
Before joining Thermo Fisher Scientific, Lowery held leadership roles at Maytag Corporation and General Motors. He holds a master’s degree in manufacturing management from Kettering University and a bachelor’s degree in mechanical engineering from Tennessee Technological University.
“I am very pleased to welcome Fred to Henry Schein. Beyond his operational experience, he brings a leadership philosophy that reflects the values that defines our company,” said Bergman. “Fred understands the role we play in supporting dental and medical practitioners, and he is well equipped to lead Henry Schein into its next phase of growth.”
Phil Laskawy, lead director and chair of the nominating and governance committee at Henry Schein, thanked Bergman for his long-standing leadership and said the board was confident that Lowery had the experience and capabilities required to guide the company forward.
“We are excited about our strategic partnership with Henry Schein and look forward to supporting the next chapter of the company’s journey under Fred’s leadership,” said Max Lin, board member and vice-chair of the nominating and governance committee at Henry Schein and partner at KKR. “Fred brings a combination of healthcare distribution experience, operational best practices, and accountable leadership that will accelerate our strategic initiatives and further differentiate Henry Schein as a business.”
